2019 IPO

Axcella Stock

Axcella is a biotechnology company providing therapeutics development solutions.

Sign up today and learn more about Axcella Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Axcella Stock

Axcella Health is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has discovered more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular level. Axcella’s proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative and liver conditions. Axcella is led by a team with a strong track record of leaving a lasting impact on the therapeutic landscape through the development of novel products.

Funding History

October 2013$10.8M
December 2013$0
May 2015$39.0M
February 2016$42.5M
November 2018$59.0M



David Berry

Senior Vice President and Chief Medical Officer

Christopher Wright


Jeff Moore

President and Chief Executive Officer

William Hinshaw

President of R&D and Chief Scientific Officer

Peter Mueller


Geoffrey von Maltzahn

Principal Research Fellow

Eugenio Ferrari

VP, Research

Michael Hamill

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: